ClinicalTrials.gg
CompletedNCT00150709Updated Feb 9, 2024Results posted

A Study Of The Safety And Efficacy Of Levetiracetam (Keppra®) (Ucb L059) In Children With Epilepsy

A Phase 3 interventional study of Levetiracetam in Epilepsy, Partial, sponsored by UCB Pharma. Completed. Open to participants aged Up to 16 Years. Per ClinicalTrials.gov, last updated 2024-02-09.

Sponsored by UCB Pharma (part of UCB S.A.) · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 7 years 7 months after the study started (first participant enrolled Jan 1998, registered Sep 2005).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
223
Allocation
Non-randomized
Ages
Up to 16 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 18 studies testing levetiracetam in Epilepsies, Partial — none open to participants now, none under way, none of them phase 3. Levetiracetam · Epilepsies, Partial.

Enrollment
8th of 18
223 · median 173
Started
1998
the only one that year
Phase 3
10 of 18
none open now
Registered
2nd of 18
by date
Lead sponsor
10 of 18
UCB Pharma

Among the 18 studies testing levetiracetam in Epilepsies, Partial, this one is the 8th largest by enrollment, is the only one that started in 1998, is one of 10 in phase 3, and was the 2nd registered.

Epilepsies, Partial

243 studies on the registry are indexed under Epilepsies, Partial; 49 are open to participants now.

Browse Epilepsies, Partial studies →

Open to participants now

None of the 18 studies testing levetiracetam in Epilepsies, Partial is open now. The open studies under Epilepsies, Partial, anywhere →

About levetiracetam

Levetiracetam: first FDA approval 1999 (KEPPRA), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 37 Epilepsies, Partial studies recruiting now, 9 (24%) set no upper age limit and 24 (65%) stop at 75 or younger; 17 take children under 18; 3 take healthy volunteers.

This study: Up to 16 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 18 studies testing levetiracetam in Epilepsies, Partial as a file.
02

Study summary

Open-label study to allow pediatric patients who have participated in prior Levetiracetam (Keppra®) studies to continue their treatment with adequate monitoring and standardized follow-up care until Levetiracetam (Keppra®) is approved for use in children or until the completion of the development program for pediatrics.

03

Conditions studied

  • Epilepsy, Partial

Keywords

  • Epilepsy
  • Pediatric
  • Partial onset epilepsy
  • Levetiracetam
  • Keppra
04

Who can participate

Ages eligible
Up to 16 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have completed Study N151, or any other applicable pediatric trials of Levetiracetam (Keppra®)
  • Be a patient for whom the treatment of Levetiracetam (Keppra®) would be of potential benefit such that the patient/parent(s)/legal guardian and the Investigator agree to continue treatment.

Exclusion criteria

Exclusion Criteria:

  • Not be on a ketogenic diet (during the course of this study).
  • Not have seizures too close together to accurately count (i.e., the patient's seizures must be countable).
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
223 participants (actual)

Study arms

  • Experimental
    N159 PBO/LEV

    Subjects had previously participated in study N159 in which they had received Placebo (PBO).

    Drug: Levetiracetam

  • Experimental
    N159 LEV/LEV

    Subjects had previously participated in study N159 in which they had received Levetiracetam (LEV).

    Drug: Levetiracetam

  • Experimental
    N01010+N151 LEV/LEV

    Subjects had previously participated in study N01010 or study N151 in which they had received Levetiracetam (LEV).

    Drug: Levetiracetam

  • Experimental
    N01052 LEV/LEV

    Subjects had previously participated in study N01052 in which they had received Levetiracetam (LEV).

    Drug: Levetiracetam

Interventions

  • * Pharmaceutical form: Oral tablets and oral solution * Route of administration: Oral use

    Also known as: Keppra

06

What researchers measure

Primary outcomes

  1. Percentage Change From Baseline in Partial Onset (Type I) Seizure Frequency Per Week Over Time During the Treatment Period

    Percentage change from Baseline of partial onset (Type I) seizure frequency over the Treatment Period standardized to 1 week Period. According to the ILAE 1981 classification, seizures can be classified into one of the following three groups: Type I (partial onset seizures), Type II (generalized seizures) and Type III (unclassified seizures). Negative values indicate an improvement from Baseline.

    Time frame: During the Treatment Period (an average of 2 years), compared to Baseline

  2. Percentage Change From Baseline in Total (Type I, II, III) Seizure Frequency Per Week Over Time During the Treatment Period

    Percentage change from Baseline in total (type I, II, III) seizure frequency over the Treatment Period standardized to 1 week Period. Seizures were categorized in Type I (partial onset seizures), Type II (generalized seizures) and Type III (unclassified seizures) according to the ILAE 1981 classification. Negative values indicate an improvement from Baseline.

    Time frame: During the Treatment Period (an average of 2 years), compared to Baseline

Secondary outcomes

  1. Absolute Change From Baseline in Partial Onset (Type I) Seizure Frequency Over Time During the Treatment Period

    Absolute change from Baseline of Partial onset (Type I) seizure frequency over the Treatment Period standardized to 1 week Period. According to the ILAE 1981 classification, seizures can be classified into one of the following three groups: Type I (partial onset seizures), Type II (generalized seizures) and Type III (unclassified seizures). Negative values indicate an improvement from Baseline.

    Time frame: During the Treatment Period (an average of 2 years), compared to Baseline

  2. Absolute Change From Baseline in Total (Type I, II, III) Seizure Frequency Per Week Over Time During the Treatment Period

    Absolute change from Baseline in total (type I, II, III) seizure frequency over the Treatment Period standardized to 1 week period. Seizures were categorized in Type I (partial onset seizures), Type II (generalized seizures) and Type III (unclassified seizures) according to the ILAE 1981 classification. Negative values indicate improvement from Baseline.

    Time frame: During the Treatment Period (an average of 2 years), compared to Baseline

  3. At Least 50% Responder Rate in Partial Onset (Type I) Seizure Frequency From Baseline Per Week During the Treatment Period

    At least 50% responder rate in Partial Onset (Type I) Seizure Frequency per Week over the Treatment Period is defined as the percentage of subjects with a reduction from baseline in Partial Onset (Type I) seizure frequency of at least 50%. According to the ILAE 1981 classification, seizures can be classified into one of the following three groups: Type I (partial onset seizures), Type II (generalized seizures) and Type III (unclassified seizures).

    Time frame: During the Treatment Period (an average of 2 years), compared to Baseline

  4. At Least 50% Responder Rate in Total (Type I, II, III) Seizure Frequency From Baseline Per Week During the Treatment Period

    At least 50% responder rate in total (Type I, II, III) Seizure Frequency per Week over the Treatment Period is defined as the percentage of subjects with a reduction from baseline in total (Type I, II, III) seizure frequency of at least 50%. Seizures were categorized in Type I (partial onset seizures), Type II (generalized seizures) and Type III (unclassified seizures) according to the ILAE 1981 classification.

    Time frame: During the Treatment Period (an average of 2 years), compared to Baseline

  5. Number of Subjects Who Are Seizure-free for at Least 7 Days During the Treatment Period

    A day was considered seizure-free if no seizures were reported for 24 hours.

    Time frame: During the Treatment Period (an average of 2 years)

  6. Cumulative Percentage of Subjects Who Are Continuously Seizure Free by Time Interval (Day 0)

    A time interval was considered seizure-free if no seizures were reported in that time interval. The Treatment Period consisted of a 6-week Titration Phase and a Maintenance Phase lasting until market approval or completion of development of levetiracetam for the pediatric indication.

    Time frame: Day 0 (beginning day of the maintenance phase)

  7. Cumulative Percentage of Subjects Who Are Continuously Seizure Free by Time Interval (Day 1 - <= 2 Months)

    A time interval was considered seizure-free if no seizures were reported in that time interval. The Treatment Period consisted of a 6-week Titration Phase and a Maintenance Phase lasting until market approval or completion of development of levetiracetam for the pediatric indication.

    Time frame: Day 1 - <= 2 months of the Maintenance Phase

  8. Cumulative Percentage of Subjects Who Are Continuously Seizure Free by Time Interval (> 2 Months - <= 4 Months)

    A time interval was considered seizure-free if no seizures were reported in that time interval. The Treatment Period consisted of a 6-week Titration Phase and a Maintenance Phase lasting until market approval or completion of development of levetiracetam for the pediatric indication.

    Time frame: > 2 months - <= 4 months of the Maintenance Phase

  9. Cumulative Percentage of Subjects Who Are Continuously Seizure Free by Time Interval (> 4 Months - <= 6 Months)

    A time interval was considered seizure-free if no seizures were reported in that time interval. The Treatment Period consisted of a 6-week Titration Phase and a Maintenance Phase lasting until market approval or completion of development of levetiracetam for the pediatric indication.

    Time frame: > 4 months - <= 6 months of the Maintenance Phase

  10. Cumulative Percentage of Subjects Who Are Continuously Seizure Free by Time Interval (> 6 Months - <= 8 Months)

    A time interval was considered seizure-free if no seizures were reported in that time interval. The Treatment Period consisted of a 6-week Titration Phase and a Maintenance Phase lasting until market approval or completion of development of levetiracetam for the pediatric indication.

    Time frame: > 6 months - <= 8 months of the Maintenance Phase

  11. Cumulative Percentage of Subjects Who Are Continuously Seizure Free by Time Interval (> 8 Months - <= 10 Months)

    A time interval was considered seizure-free if no seizures were reported in that time interval. The Treatment Period consisted of a 6-week Titration Phase and a Maintenance Phase lasting until market approval or completion of development of levetiracetam for the pediatric indication.

    Time frame: > 8 months - <= 10 months of the Maintenance Phase

  12. Cumulative Percentage of Subjects Who Are Continuously Seizure Free by Time Interval (> 10 Months - <= 12 Months)

    A time interval was considered seizure-free if no seizures were reported in that time interval. The Treatment Period consisted of a 6-week Titration Phase and a Maintenance Phase lasting until market approval or completion of development of levetiracetam for the pediatric indication.

    Time frame: > 10 months - <= 12 months of the Maintenance Phase

  13. Cumulative Percentage of Subjects Who Are Continuously Seizure Free by Time Interval (> 12 Months - <= 14 Months)

    A time interval was considered seizure-free if no seizures were reported in that time interval. The Treatment Period consisted of a 6-week Titration Phase and a Maintenance Phase lasting until market approval or completion of development of levetiracetam for the pediatric indication.

    Time frame: > 12 months - <= 14 months of the Maintenance Phase

  14. Cumulative Percentage of Subjects Who Are Continuously Seizure Free by Time Interval (> 14 Months - <= 16 Months)

    A time interval was considered seizure-free if no seizures were reported in that time interval. The Treatment Period consisted of a 6-week Titration Phase and a Maintenance Phase lasting until market approval or completion of development of levetiracetam for the pediatric indication.

    Time frame: > 14 months - <= 16 months of the Maintenance Phase

  15. Cumulative Percentage of Subjects Who Are Continuously Seizure Free by Time Interval (> 16 Months - <= 18 Months)

    A time interval was considered seizure-free if no seizures were reported in that time interval. The Treatment Period consisted of a 6-week Titration Phase and a Maintenance Phase lasting until market approval or completion of development of levetiracetam for the pediatric indication.

    Time frame: > 16 months - <= 18 months of the Maintenance Phase

  16. Cumulative Percentage of Subjects Who Are Continuously Seizure Free by Time Interval (> 18 Months - <= 20 Months)

    A time interval was considered seizure-free if no seizures were reported in that time interval. The Treatment Period consisted of a 6-week Titration Phase and a Maintenance Phase lasting until market approval or completion of development of levetiracetam for the pediatric indication.

    Time frame: > 18 months - <= 20 months of the Maintenance Phase

  17. Number of Seizures by Type During the Treatment Period

    Number of following seizure types were assessed: Total seizures (Type I, II, III), Total Type I seizures, Total Type II seizures, Total Type III seizures

    Time frame: During the Treatment Period (an average of 2 years)

  18. Percentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 1

    Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The Global Evaluation Scale (GES) is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit). The reference time point for Visit 1 is in the respective feeder study of the participant.

    Time frame: Visit 1 (Screening Visit (Week 0))

  19. Percentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Titration Visit 1

    Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The Global Evaluation Scale (GES) is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

    Time frame: Titration Visit 1 (Week 2)

  20. Percentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Titration Visit 2

    Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

    Time frame: Titration Visit 2 (Week 4)

  21. Percentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Titration Visit 3

    Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

    Time frame: Titration Visit 3 (Week 6)

  22. Percentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 2

    Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

    Time frame: Visit 2 (Month 2)

  23. Percentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 3

    Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

    Time frame: Visit 3 (Month 4)

  24. Percentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 4

    Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

    Time frame: Visit 4 (Month 6)

  25. Percentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 5

    Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

    Time frame: Visit 5 (Month 9)

  26. Percentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 6

    Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

    Time frame: Visit 6 (Month 12)

  27. Percentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 7

    Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

    Time frame: Visit 7 (Month 15)

  28. Percentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 8

    Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

    Time frame: Visit 8 (Month 18)

  29. Percentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 9

    Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

    Time frame: Visit 9 (Month 21)

  30. Percentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 10

    Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

    Time frame: Visit 10 (Month 24)

  31. Percentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 11

    Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

    Time frame: Visit 11 (Month 27)

  32. Percentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 12

    Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

    Time frame: Visit 12 (Month 30)

  33. Percentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 13

    Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

    Time frame: Visit 13 (Month 33)

  34. Percentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 14

    Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

    Time frame: Visit 14 (Month 36)

  35. Percentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 15

    Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

    Time frame: Visit 15 (Month 39)

  36. Percentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 16

    Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

    Time frame: Visit 16 (Month 42)

  37. Percentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 17

    Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

    Time frame: Visit 17 (Month 45)

  38. Percentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 18

    Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

    Time frame: Visit 18 (Month 48)

  39. Percentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 19

    Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

    Time frame: Visit 19 (Month 51)

  40. Percentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 20

    Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

    Time frame: Visit 20 (Month 54)

  41. Percentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 21

    Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

    Time frame: Visit 21 (Month 57)

  42. Percentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 22

    Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

    Time frame: Visit 22 (Month 60)

  43. Percentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 23

    Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

    Time frame: Visit 23 (Month 63)

  44. Percentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 24

    Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

    Time frame: Visit 24 (Month 66)

  45. Percentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 25

    Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

    Time frame: Visit 25 (Month 69)

  46. Percentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 26

    Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

    Time frame: Visit 26 (Month 72)

  47. Percentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 27

    Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

    Time frame: Visit 27 (Month 75)

  48. Percentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 28

    Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

    Time frame: Visit 28 (Month 78)

  49. Percentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 29

    Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

    Time frame: Visit 29 (Month 81)

  50. Percentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 30

    Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

    Time frame: Visit 30 (Month 84)

  51. Percentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 31

    Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

    Time frame: Visit 31 (Month 87)

  52. Percentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Withdrawal Visit

    Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

    Time frame: Withdrawal visit (up to Month 90)

  53. Percentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Final Visit

    Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

    Time frame: Final visit (up to Month 90)

  54. Percentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 1

    Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit). The reference time point for Visit 1 is in the respective feeder study of the participant.

    Time frame: Visit 1 (Screening Visit (Week 0))

  55. Percentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Titration Visit 1

    Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

    Time frame: Titration Visit 1 (Week 2)

  56. Percentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Titration Visit 2

    Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

    Time frame: Titration Visit 2 (Week 4)

  57. Percentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Titration Visit 3

    Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

    Time frame: Titration Visit 3 (Week 6)

  58. Percentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 2

    Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

    Time frame: Visit 2 (Month 2)

  59. Percentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 3

    Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

    Time frame: Visit 3 (Month 4)

  60. Percentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 4

    Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

    Time frame: Visit 4 (Month 6)

  61. Percentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 5

    Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

    Time frame: Visit 5 (Month 9)

  62. Percentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 6

    Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

    Time frame: Visit 6 (Month 12)

  63. Percentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 7

    Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

    Time frame: Visit 7 (Month 15)

  64. Percentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 8

    Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

    Time frame: Visit 8 (Month 18)

  65. Percentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 9

    Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

    Time frame: Visit 9 (Month 21)

  66. Percentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 10

    Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

    Time frame: Visit 10 (Month 24)

  67. Percentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 11

    Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

    Time frame: Visit 11 (Month 27)

  68. Percentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 12

    Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

    Time frame: Visit 12 (Month 30)

  69. Percentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 13

    Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

    Time frame: Visit 13 (Month 33)

  70. Percentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 14

    Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

    Time frame: Visit 14 (Month 36)

  71. Percentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 15

    Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

    Time frame: Visit 15 (Month 39)

  72. Percentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 16

    Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

    Time frame: Visit 16 (Month 42)

  73. Percentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 17

    Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

    Time frame: Visit 17 (Month 45)

  74. Percentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 18

    Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

    Time frame: Visit 18 (Month 48)

  75. Percentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 19

    Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

    Time frame: Visit 19 (Month 51)

  76. Percentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 20

    Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

    Time frame: Visit 20 (Month 54)

  77. Percentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 21

    Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

    Time frame: Visit 21 (Month 57)

  78. Percentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 22

    Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

    Time frame: Visit 22 (Month 60)

  79. Percentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 23

    Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

    Time frame: Visit 23 (Month 63)

  80. Percentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 24

    Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

    Time frame: Visit 24 (Month 66)

  81. Percentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 25

    Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

    Time frame: Visit 25 (Month 69)

  82. Percentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 26

    Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

    Time frame: Visit 26 (Month 72)

  83. Percentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 27

    Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

    Time frame: Visit 27 (Month 75)

  84. Percentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 28

    Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

    Time frame: Visit 28 (Month 78)

  85. Percentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 29

    Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

    Time frame: Visit 29 (Month 81)

  86. Percentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 30

    Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

    Time frame: Visit 30 (Month 84)

  87. Percentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 31

    Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

    Time frame: Visit 31 (Month 87)

  88. Percentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Withdrawal Visit

    Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

    Time frame: Withdrawal visit (up to Month 90)

  89. Percentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Final Visit

    Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

    Time frame: Final visit (up to Month 90)

07

Results

Posted Feb 9, 2024

Participant flow

The study started to enroll patients in February 1998 and concluded in January 2006.

Participant flow — Overall Study
MilestoneN159 PBO/LEVN159 LEV/LEVN01010+N151 LEV/LEVN01052 LEV/LEV
Started79894114
Completed2427176
Not completed5562248
Withdrew: Protocol violation7831
Withdrew: Adverse event8223
Withdrew: Lack of efficacy61190
Withdrew: Withdrawal by subject71050
Withdrew: Lost to follow-up3200
Withdrew: Sponsor decision0001
Withdrew: Site/investigator discontinued the study5520
Withdrew: Decision of parent(s)1200
Withdrew: Decision of parent(s) and investigator3000
Withdrew: Loss/ incompleteness of efficacy121222
Withdrew: Investigator decision1001
Withdrew: Subject relocated2210
Withdrew: Subject continues keppra through prescriptions0400
Withdrew: Convenience0100
Withdrew: Subject entered new drug study0100
Withdrew: Subject to undergo surgery for seizures0100
Withdrew: Lack of ease of swallowing0100

Outcome measures

PrimaryPercentage Change From Baseline in Partial Onset (Type I) Seizure Frequency Per Week Over Time During the Treatment Period

Percentage change from Baseline of partial onset (Type I) seizure frequency over the Treatment Period standardized to 1 week Period. According to the ILAE 1981 classification, seizures can be classified into one of the following three groups: Type I (partial onset seizures), Type II (generalized seizures) and Type III (unclassified seizures). Negative values indicate an improvement from Baseline.

Time frame:
During the Treatment Period (an average of 2 years), compared to Baseline
Reported as:
Median · percentage of change
Percentage Change From Baseline in Partial Onset (Type I) Seizure Frequency Per Week Over Time During the Treatment Period
percentage of changeN159 PBO/LEVN159 LEV/LEVN01010+N151 LEV/LEVN01052 LEV/LEV
Percentage Change From Baseline in Partial Onset (Type I) Seizure Frequency Per Week Over Time During the Treatment Period-66.4 (-90.0 to -22.3)-47.8 (-76.2 to -25.4)-66.4 (-93.6 to -5.6)—
PrimaryPercentage Change From Baseline in Total (Type I, II, III) Seizure Frequency Per Week Over Time During the Treatment Period

Percentage change from Baseline in total (type I, II, III) seizure frequency over the Treatment Period standardized to 1 week Period. Seizures were categorized in Type I (partial onset seizures), Type II (generalized seizures) and Type III (unclassified seizures) according to the ILAE 1981 classification. Negative values indicate an improvement from Baseline.

Time frame:
During the Treatment Period (an average of 2 years), compared to Baseline
Reported as:
Median · percentage of change
Percentage Change From Baseline in Total (Type I, II, III) Seizure Frequency Per Week Over Time During the Treatment Period
percentage of changeN159 PBO/LEVN159 LEV/LEVN01010+N151 LEV/LEVN01052 LEV/LEV
Percentage Change From Baseline in Total (Type I, II, III) Seizure Frequency Per Week Over Time During the Treatment Period-66.4 (-90.0 to -25.2)-45.7 (-73.6 to -17.4)-65.9 (-93.1 to -5.6)—
SecondaryAbsolute Change From Baseline in Partial Onset (Type I) Seizure Frequency Over Time During the Treatment Period

Absolute change from Baseline of Partial onset (Type I) seizure frequency over the Treatment Period standardized to 1 week Period. According to the ILAE 1981 classification, seizures can be classified into one of the following three groups: Type I (partial onset seizures), Type II (generalized seizures) and Type III (unclassified seizures). Negative values indicate an improvement from Baseline.

Time frame:
During the Treatment Period (an average of 2 years), compared to Baseline
Reported as:
Median · partial seizure frequency per week
Absolute Change From Baseline in Partial Onset (Type I) Seizure Frequency Over Time During the Treatment Period
partial seizure frequency per weekN159 PBO/LEVN159 LEV/LEVN01010+N151 LEV/LEVN01052 LEV/LEV
Absolute Change From Baseline in Partial Onset (Type I) Seizure Frequency Over Time During the Treatment Period-2.1 (-7.4 to -0.3)-1.6 (-6.6 to -0.6)-1.5 (-7.4 to 0.0)—
SecondaryAbsolute Change From Baseline in Total (Type I, II, III) Seizure Frequency Per Week Over Time During the Treatment Period

Absolute change from Baseline in total (type I, II, III) seizure frequency over the Treatment Period standardized to 1 week period. Seizures were categorized in Type I (partial onset seizures), Type II (generalized seizures) and Type III (unclassified seizures) according to the ILAE 1981 classification. Negative values indicate improvement from Baseline.

Time frame:
During the Treatment Period (an average of 2 years), compared to Baseline
Reported as:
Median · partial seizure frequency per week
Absolute Change From Baseline in Total (Type I, II, III) Seizure Frequency Per Week Over Time During the Treatment Period
partial seizure frequency per weekN159 PBO/LEVN159 LEV/LEVN01010+N151 LEV/LEVN01052 LEV/LEV
Absolute Change From Baseline in Total (Type I, II, III) Seizure Frequency Per Week Over Time During the Treatment Period-2.1 (-7.4 to -0.6)-1.5 (-6.4 to -0.5)-1.1 (-7.3 to 0.0)—
SecondaryAt Least 50% Responder Rate in Partial Onset (Type I) Seizure Frequency From Baseline Per Week During the Treatment Period

At least 50% responder rate in Partial Onset (Type I) Seizure Frequency per Week over the Treatment Period is defined as the percentage of subjects with a reduction from baseline in Partial Onset (Type I) seizure frequency of at least 50%. According to the ILAE 1981 classification, seizures can be classified into one of the following three groups: Type I (partial onset seizures), Type II (generalized seizures) and Type III (unclassified seizures).

Time frame:
During the Treatment Period (an average of 2 years), compared to Baseline
Reported as:
Number · percentage of participants
At Least 50% Responder Rate in Partial Onset (Type I) Seizure Frequency From Baseline Per Week During the Treatment Period
percentage of participantsN159 PBO/LEVN159 LEV/LEVN01010+N151 LEV/LEVN01052 LEV/LEV
At Least 50% Responder Rate in Partial Onset (Type I) Seizure Frequency From Baseline Per Week During the Treatment Period58.447.762.2—
SecondaryAt Least 50% Responder Rate in Total (Type I, II, III) Seizure Frequency From Baseline Per Week During the Treatment Period

At least 50% responder rate in total (Type I, II, III) Seizure Frequency per Week over the Treatment Period is defined as the percentage of subjects with a reduction from baseline in total (Type I, II, III) seizure frequency of at least 50%. Seizures were categorized in Type I (partial onset seizures), Type II (generalized seizures) and Type III (unclassified seizures) according to the ILAE 1981 classification.

Time frame:
During the Treatment Period (an average of 2 years), compared to Baseline
Reported as:
Number · percentage of participants
At Least 50% Responder Rate in Total (Type I, II, III) Seizure Frequency From Baseline Per Week During the Treatment Period
percentage of participantsN159 PBO/LEVN159 LEV/LEVN01010+N151 LEV/LEVN01052 LEV/LEV
At Least 50% Responder Rate in Total (Type I, II, III) Seizure Frequency From Baseline Per Week During the Treatment Period58.446.662.2—
SecondaryNumber of Subjects Who Are Seizure-free for at Least 7 Days During the Treatment Period

A day was considered seizure-free if no seizures were reported for 24 hours.

Time frame:
During the Treatment Period (an average of 2 years)
Reported as:
Count of participants · Participants
Number of Subjects Who Are Seizure-free for at Least 7 Days During the Treatment Period
ParticipantsN159 PBO/LEVN159 LEV/LEVN01010+N151 LEV/LEVN01052 LEV/LEV
Number of Subjects Who Are Seizure-free for at Least 7 Days During the Treatment Period74734010
SecondaryCumulative Percentage of Subjects Who Are Continuously Seizure Free by Time Interval (Day 0)

A time interval was considered seizure-free if no seizures were reported in that time interval. The Treatment Period consisted of a 6-week Titration Phase and a Maintenance Phase lasting until market approval or completion of development of levetiracetam for the pediatric indication.

Time frame:
Day 0 (beginning day of the maintenance phase)
Reported as:
Number · percentage of participants
Cumulative Percentage of Subjects Who Are Continuously Seizure Free by Time Interval (Day 0)
percentage of participantsN159 PBO/LEVN159 LEV/LEVN01010+N151 LEV/LEVN01052 LEV/LEV
Cumulative Percentage of Subjects Who Are Continuously Seizure Free by Time Interval (Day 0)74.064.075.038.5
SecondaryCumulative Percentage of Subjects Who Are Continuously Seizure Free by Time Interval (Day 1 - <= 2 Months)

A time interval was considered seizure-free if no seizures were reported in that time interval. The Treatment Period consisted of a 6-week Titration Phase and a Maintenance Phase lasting until market approval or completion of development of levetiracetam for the pediatric indication.

Time frame:
Day 1 - <= 2 months of the Maintenance Phase
Reported as:
Number · percentage of participants
Cumulative Percentage of Subjects Who Are Continuously Seizure Free by Time Interval (Day 1 - <= 2 Months)
percentage of participantsN159 PBO/LEVN159 LEV/LEVN01010+N151 LEV/LEVN01052 LEV/LEV
Cumulative Percentage of Subjects Who Are Continuously Seizure Free by Time Interval (Day 1 - <= 2 Months)16.415.127.523.1
SecondaryCumulative Percentage of Subjects Who Are Continuously Seizure Free by Time Interval (> 2 Months - <= 4 Months)

A time interval was considered seizure-free if no seizures were reported in that time interval. The Treatment Period consisted of a 6-week Titration Phase and a Maintenance Phase lasting until market approval or completion of development of levetiracetam for the pediatric indication.

Time frame:
> 2 months - <= 4 months of the Maintenance Phase
Reported as:
Number · percentage of participants
Cumulative Percentage of Subjects Who Are Continuously Seizure Free by Time Interval (> 2 Months - <= 4 Months)
percentage of participantsN159 PBO/LEVN159 LEV/LEVN01010+N151 LEV/LEVN01052 LEV/LEV
Cumulative Percentage of Subjects Who Are Continuously Seizure Free by Time Interval (> 2 Months - <= 4 Months)12.312.817.523.1
SecondaryCumulative Percentage of Subjects Who Are Continuously Seizure Free by Time Interval (> 4 Months - <= 6 Months)

A time interval was considered seizure-free if no seizures were reported in that time interval. The Treatment Period consisted of a 6-week Titration Phase and a Maintenance Phase lasting until market approval or completion of development of levetiracetam for the pediatric indication.

Time frame:
> 4 months - <= 6 months of the Maintenance Phase
Reported as:
Number · percentage of participants
Cumulative Percentage of Subjects Who Are Continuously Seizure Free by Time Interval (> 4 Months - <= 6 Months)
percentage of participantsN159 PBO/LEVN159 LEV/LEVN01010+N151 LEV/LEVN01052 LEV/LEV
Cumulative Percentage of Subjects Who Are Continuously Seizure Free by Time Interval (> 4 Months - <= 6 Months)11.09.315.011.5
SecondaryCumulative Percentage of Subjects Who Are Continuously Seizure Free by Time Interval (> 6 Months - <= 8 Months)

A time interval was considered seizure-free if no seizures were reported in that time interval. The Treatment Period consisted of a 6-week Titration Phase and a Maintenance Phase lasting until market approval or completion of development of levetiracetam for the pediatric indication.

Time frame:
> 6 months - <= 8 months of the Maintenance Phase
Reported as:
Number · percentage of participants
Cumulative Percentage of Subjects Who Are Continuously Seizure Free by Time Interval (> 6 Months - <= 8 Months)
percentage of participantsN159 PBO/LEVN159 LEV/LEVN01010+N151 LEV/LEVN01052 LEV/LEV
Cumulative Percentage of Subjects Who Are Continuously Seizure Free by Time Interval (> 6 Months - <= 8 Months)8.24.712.511.5
SecondaryCumulative Percentage of Subjects Who Are Continuously Seizure Free by Time Interval (> 8 Months - <= 10 Months)

A time interval was considered seizure-free if no seizures were reported in that time interval. The Treatment Period consisted of a 6-week Titration Phase and a Maintenance Phase lasting until market approval or completion of development of levetiracetam for the pediatric indication.

Time frame:
> 8 months - <= 10 months of the Maintenance Phase
Reported as:
Number · percentage of participants
Cumulative Percentage of Subjects Who Are Continuously Seizure Free by Time Interval (> 8 Months - <= 10 Months)
percentage of participantsN159 PBO/LEVN159 LEV/LEVN01010+N151 LEV/LEVN01052 LEV/LEV
Cumulative Percentage of Subjects Who Are Continuously Seizure Free by Time Interval (> 8 Months - <= 10 Months)5.53.510.011.5
SecondaryCumulative Percentage of Subjects Who Are Continuously Seizure Free by Time Interval (> 10 Months - <= 12 Months)

A time interval was considered seizure-free if no seizures were reported in that time interval. The Treatment Period consisted of a 6-week Titration Phase and a Maintenance Phase lasting until market approval or completion of development of levetiracetam for the pediatric indication.

Time frame:
> 10 months - <= 12 months of the Maintenance Phase
Reported as:
Number · percentage of participants
Cumulative Percentage of Subjects Who Are Continuously Seizure Free by Time Interval (> 10 Months - <= 12 Months)
percentage of participantsN159 PBO/LEVN159 LEV/LEVN01010+N151 LEV/LEVN01052 LEV/LEV
Cumulative Percentage of Subjects Who Are Continuously Seizure Free by Time Interval (> 10 Months - <= 12 Months)1.43.57.511.5
SecondaryCumulative Percentage of Subjects Who Are Continuously Seizure Free by Time Interval (> 12 Months - <= 14 Months)

A time interval was considered seizure-free if no seizures were reported in that time interval. The Treatment Period consisted of a 6-week Titration Phase and a Maintenance Phase lasting until market approval or completion of development of levetiracetam for the pediatric indication.

Time frame:
> 12 months - <= 14 months of the Maintenance Phase
Reported as:
Number · percentage of participants
Cumulative Percentage of Subjects Who Are Continuously Seizure Free by Time Interval (> 12 Months - <= 14 Months)
percentage of participantsN159 PBO/LEVN159 LEV/LEVN01010+N151 LEV/LEVN01052 LEV/LEV
Cumulative Percentage of Subjects Who Are Continuously Seizure Free by Time Interval (> 12 Months - <= 14 Months)1.42.35.011.5
SecondaryCumulative Percentage of Subjects Who Are Continuously Seizure Free by Time Interval (> 14 Months - <= 16 Months)

A time interval was considered seizure-free if no seizures were reported in that time interval. The Treatment Period consisted of a 6-week Titration Phase and a Maintenance Phase lasting until market approval or completion of development of levetiracetam for the pediatric indication.

Time frame:
> 14 months - <= 16 months of the Maintenance Phase
Reported as:
Number · percentage of participants
Cumulative Percentage of Subjects Who Are Continuously Seizure Free by Time Interval (> 14 Months - <= 16 Months)
percentage of participantsN159 PBO/LEVN159 LEV/LEVN01010+N151 LEV/LEVN01052 LEV/LEV
Cumulative Percentage of Subjects Who Are Continuously Seizure Free by Time Interval (> 14 Months - <= 16 Months)1.42.35.011.5
SecondaryCumulative Percentage of Subjects Who Are Continuously Seizure Free by Time Interval (> 16 Months - <= 18 Months)

A time interval was considered seizure-free if no seizures were reported in that time interval. The Treatment Period consisted of a 6-week Titration Phase and a Maintenance Phase lasting until market approval or completion of development of levetiracetam for the pediatric indication.

Time frame:
> 16 months - <= 18 months of the Maintenance Phase
Reported as:
Number · percentage of participants
Cumulative Percentage of Subjects Who Are Continuously Seizure Free by Time Interval (> 16 Months - <= 18 Months)
percentage of participantsN159 PBO/LEVN159 LEV/LEVN01010+N151 LEV/LEVN01052 LEV/LEV
Cumulative Percentage of Subjects Who Are Continuously Seizure Free by Time Interval (> 16 Months - <= 18 Months)1.42.32.511.5
SecondaryCumulative Percentage of Subjects Who Are Continuously Seizure Free by Time Interval (> 18 Months - <= 20 Months)

A time interval was considered seizure-free if no seizures were reported in that time interval. The Treatment Period consisted of a 6-week Titration Phase and a Maintenance Phase lasting until market approval or completion of development of levetiracetam for the pediatric indication.

Time frame:
> 18 months - <= 20 months of the Maintenance Phase
Reported as:
Number · percentage of participants
Cumulative Percentage of Subjects Who Are Continuously Seizure Free by Time Interval (> 18 Months - <= 20 Months)
percentage of participantsN159 PBO/LEVN159 LEV/LEVN01010+N151 LEV/LEVN01052 LEV/LEV
Cumulative Percentage of Subjects Who Are Continuously Seizure Free by Time Interval (> 18 Months - <= 20 Months)1.42.32.511.5
SecondaryNumber of Seizures by Type During the Treatment Period

Number of following seizure types were assessed: Total seizures (Type I, II, III), Total Type I seizures, Total Type II seizures, Total Type III seizures

Time frame:
During the Treatment Period (an average of 2 years)
Reported as:
Number · seizures
Number of Seizures by Type During the Treatment Period
seizuresN159 PBO/LEVN159 LEV/LEVN01010+N151 LEV/LEVN01052 LEV/LEV
Total seizures (Type I, II, III)42132701212423219914
Total Type I seizures39147574642408913675
Total Type II seizures2142126561426239
Total Type III seizures843110
SecondaryPercentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 1

Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The Global Evaluation Scale (GES) is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit). The reference time point for Visit 1 is in the respective feeder study of the participant.

Time frame:
Visit 1 (Screening Visit (Week 0))
Reported as:
Number · percentage of participants
Percentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 1
percentage of participantsN159 PBO/LEVN159 LEV/LEVN01010+N151 LEV/LEVN01052 LEV/LEV
Marked improvement7.711.229.30.0
Moderate improvement21.818.012.20.0
Slight improvement12.824.719.50.0
No change47.440.426.8100.0
Slight worsening5.15.612.20.0
Moderate worsening3.80.00.00.0
Marked worsening0.00.00.00.0
Not done1.30.00.00.0
SecondaryPercentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Titration Visit 1

Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The Global Evaluation Scale (GES) is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

Time frame:
Titration Visit 1 (Week 2)
Reported as:
Number · percentage of participants
Percentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Titration Visit 1
percentage of participantsN159 PBO/LEVN159 LEV/LEVN01010+N151 LEV/LEVN01052 LEV/LEV
Marked improvement14.96.1——
Moderate improvement14.914.6——
Slight improvement32.418.3——
No change33.847.6——
Slight worsening4.19.8——
Moderate worsening0.02.4——
Marked worsening0.00.0——
Not done0.01.2——
SecondaryPercentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Titration Visit 2

Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

Time frame:
Titration Visit 2 (Week 4)
Reported as:
Number · percentage of participants
Percentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Titration Visit 2
percentage of participantsN159 PBO/LEVN159 LEV/LEVN01010+N151 LEV/LEVN01052 LEV/LEV
Marked improvement10.713.1——
Moderate improvement20.08.3——
Slight improvement20.015.5——
No change37.346.4——
Slight worsening9.311.9——
Moderate worsening2.72.4——
Marked worsening0.00.0——
Not done0.02.4——
SecondaryPercentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Titration Visit 3

Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

Time frame:
Titration Visit 3 (Week 6)
Reported as:
Number · percentage of participants
Percentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Titration Visit 3
percentage of participantsN159 PBO/LEVN159 LEV/LEVN01010+N151 LEV/LEVN01052 LEV/LEV
Marked improvement10.44.1——
Moderate improvement14.98.2——
Slight improvement17.921.9——
No change41.847.9——
Slight worsening7.59.6——
Moderate worsening4.54.1——
Marked worsening0.01.4——
Not done3.02.7——
SecondaryPercentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 2

Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

Time frame:
Visit 2 (Month 2)
Reported as:
Number · percentage of participants
Percentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 2
percentage of participantsN159 PBO/LEVN159 LEV/LEVN01010+N151 LEV/LEVN01052 LEV/LEV
Marked improvement4.18.320.516.7
Moderate improvement15.114.320.516.7
Slight improvement26.017.925.625.0
No change34.246.428.216.7
Slight worsening15.18.32.60.0
Moderate worsening2.72.42.68.3
Marked worsening1.42.40.016.7
Not done1.40.00.00.0
SecondaryPercentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 3

Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

Time frame:
Visit 3 (Month 4)
Reported as:
Number · percentage of participants
Percentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 3
percentage of participantsN159 PBO/LEVN159 LEV/LEVN01010+N151 LEV/LEVN01052 LEV/LEV
Marked improvement4.46.515.820.0
Moderate improvement7.43.915.80.0
Slight improvement20.614.326.330.0
No change41.250.634.240.0
Slight worsening20.620.87.910.0
Moderate worsening5.93.90.00.0
Marked worsening0.00.00.00.0
Not done0.00.00.00.0
SecondaryPercentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 4

Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

Time frame:
Visit 4 (Month 6)
Reported as:
Number · percentage of participants
Percentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 4
percentage of participantsN159 PBO/LEVN159 LEV/LEVN01010+N151 LEV/LEVN01052 LEV/LEV
Marked improvement4.84.014.310.0
Moderate improvement6.310.717.110.0
Slight improvement23.828.08.610.0
No change42.934.742.960.0
Slight worsening12.717.314.310.0
Moderate worsening7.94.02.90.0
Marked worsening0.00.00.00.0
Not done1.61.30.00.0
SecondaryPercentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 5

Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

Time frame:
Visit 5 (Month 9)
Reported as:
Number · percentage of participants
Percentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 5
percentage of participantsN159 PBO/LEVN159 LEV/LEVN01010+N151 LEV/LEVN01052 LEV/LEV
Marked improvement3.46.23.10.0
Moderate improvement13.66.215.622.2
Slight improvement25.418.59.422.2
No change35.646.253.144.4
Slight worsening18.616.912.50.0
Moderate worsening3.44.66.311.1
Marked worsening0.01.50.00.0
Not done0.00.00.00.0
SecondaryPercentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 6

Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

Time frame:
Visit 6 (Month 12)
Reported as:
Number · percentage of participants
Percentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 6
percentage of participantsN159 PBO/LEVN159 LEV/LEVN01010+N151 LEV/LEVN01052 LEV/LEV
Marked improvement5.61.610.711.1
Moderate improvement16.713.114.311.1
Slight improvement22.219.717.922.2
No change29.641.039.355.6
Slight worsening20.418.014.30.0
Moderate worsening3.76.63.60.0
Marked worsening1.90.00.00.0
Not done0.00.00.00.0
SecondaryPercentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 7

Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

Time frame:
Visit 7 (Month 15)
Reported as:
Number · percentage of participants
Percentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 7
percentage of participantsN159 PBO/LEVN159 LEV/LEVN01010+N151 LEV/LEVN01052 LEV/LEV
Marked improvement12.89.63.60.0
Moderate improvement4.313.57.10.0
Slight improvement23.411.514.337.5
No change42.640.439.337.5
Slight worsening12.821.225.012.5
Moderate worsening2.11.910.712.5
Marked worsening2.11.90.00.0
Not done0.00.00.00.0
SecondaryPercentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 8

Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

Time frame:
Visit 8 (Month 18)
Reported as:
Number · percentage of participants
Percentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 8
percentage of participantsN159 PBO/LEVN159 LEV/LEVN01010+N151 LEV/LEVN01052 LEV/LEV
Marked improvement10.03.93.616.7
Moderate improvement5.011.817.90.0
Slight improvement20.023.514.316.7
No change37.539.242.966.7
Slight worsening25.017.614.30.0
Moderate worsening2.53.97.10.0
Marked worsening0.00.00.00.0
Not done0.00.00.00.0
SecondaryPercentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 9

Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

Time frame:
Visit 9 (Month 21)
Reported as:
Number · percentage of participants
Percentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 9
percentage of participantsN159 PBO/LEVN159 LEV/LEVN01010+N151 LEV/LEVN01052 LEV/LEV
Marked improvement5.18.214.80.0
Moderate improvement7.714.311.10.0
Slight improvement12.822.422.20.0
No change48.734.733.380.0
Slight worsening23.118.47.420.0
Moderate worsening2.60.07.40.0
Marked worsening0.02.03.70.0
Not done0.00.00.00.0
SecondaryPercentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 10

Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

Time frame:
Visit 10 (Month 24)
Reported as:
Number · percentage of participants
Percentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 10
percentage of participantsN159 PBO/LEVN159 LEV/LEVN01010+N151 LEV/LEVN01052 LEV/LEV
Marked improvement5.76.44.00.0
Moderate improvement8.612.88.00.0
Slight improvement22.917.020.00.0
No change45.751.148.066.7
Slight worsening11.412.820.016.7
Moderate worsening5.70.00.016.7
Marked worsening0.00.00.00.0
Not done0.00.00.00.0
SecondaryPercentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 11

Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

Time frame:
Visit 11 (Month 27)
Reported as:
Number · percentage of participants
Percentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 11
percentage of participantsN159 PBO/LEVN159 LEV/LEVN01010+N151 LEV/LEVN01052 LEV/LEV
Marked improvement9.42.34.50.0
Moderate improvement9.46.822.720.0
Slight improvement21.920.513.620.0
No change50.045.554.560.0
Slight worsening6.315.94.50.0
Moderate worsening0.04.50.00.0
Marked worsening0.02.30.00.0
Not done3.12.30.00.0
SecondaryPercentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 12

Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

Time frame:
Visit 12 (Month 30)
Reported as:
Number · percentage of participants
Percentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 12
percentage of participantsN159 PBO/LEVN159 LEV/LEVN01010+N151 LEV/LEVN01052 LEV/LEV
Marked improvement6.75.10.00.0
Moderate improvement6.715.45.60.0
Slight improvement33.325.611.125.0
No change33.343.661.175.0
Slight worsening16.77.711.10.0
Moderate worsening0.02.611.10.0
Marked worsening3.30.00.00.0
Not done0.00.00.00.0
SecondaryPercentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 13

Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

Time frame:
Visit 13 (Month 33)
Reported as:
Number · percentage of participants
Percentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 13
percentage of participantsN159 PBO/LEVN159 LEV/LEVN01010+N151 LEV/LEVN01052 LEV/LEV
Marked improvement3.83.30.00.0
Moderate improvement7.76.711.10.0
Slight improvement34.623.322.250.0
No change38.546.755.650.0
Slight worsening15.416.711.10.0
Moderate worsening0.03.30.00.0
Marked worsening0.00.00.00.0
Not done0.00.00.00.0
SecondaryPercentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 14

Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

Time frame:
Visit 14 (Month 36)
Reported as:
Number · percentage of participants
Percentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 14
percentage of participantsN159 PBO/LEVN159 LEV/LEVN01010+N151 LEV/LEVN01052 LEV/LEV
Marked improvement13.34.20.0—
Moderate improvement0.00.00.0—
Slight improvement33.316.711.1—
No change40.045.866.7—
Slight worsening13.325.011.1—
Moderate worsening0.08.311.1—
Marked worsening0.00.00.0—
Not done0.00.00.0—
SecondaryPercentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 15

Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

Time frame:
Visit 15 (Month 39)
Reported as:
Number · percentage of participants
Percentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 15
percentage of participantsN159 PBO/LEVN159 LEV/LEVN01010+N151 LEV/LEVN01052 LEV/LEV
Marked improvement6.70.00.0—
Moderate improvement0.00.014.3—
Slight improvement26.728.614.3—
No change46.761.957.1—
Slight worsening6.79.514.3—
Moderate worsening13.30.00.0—
Marked worsening0.00.00.0—
Not done0.00.00.0—
SecondaryPercentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 16

Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

Time frame:
Visit 16 (Month 42)
Reported as:
Number · percentage of participants
Percentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 16
percentage of participantsN159 PBO/LEVN159 LEV/LEVN01010+N151 LEV/LEVN01052 LEV/LEV
Marked improvement0.00.00.0—
Moderate improvement0.05.60.0—
Slight improvement35.711.114.3—
No change42.961.185.7—
Slight worsening14.316.70.0—
Moderate worsening7.10.00.0—
Marked worsening0.05.60.0—
Not done0.00.00.0—
SecondaryPercentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 17

Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

Time frame:
Visit 17 (Month 45)
Reported as:
Number · percentage of participants
Percentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 17
percentage of participantsN159 PBO/LEVN159 LEV/LEVN01010+N151 LEV/LEVN01052 LEV/LEV
Marked improvement7.711.80.0—
Moderate improvement0.00.016.7—
Slight improvement38.517.60.0—
No change53.847.183.3—
Slight worsening0.023.50.0—
Moderate worsening0.00.00.0—
Marked worsening0.00.00.0—
Not done0.00.00.0—
SecondaryPercentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 18

Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

Time frame:
Visit 18 (Month 48)
Reported as:
Number · percentage of participants
Percentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 18
percentage of participantsN159 PBO/LEVN159 LEV/LEVN01010+N151 LEV/LEVN01052 LEV/LEV
Marked improvement7.715.416.7—
Moderate improvement0.00.00.0—
Slight improvement15.430.816.7—
No change46.238.550.0—
Slight worsening30.815.40.0—
Moderate worsening0.00.016.7—
Marked worsening0.00.00.0—
Not done0.00.00.0—
SecondaryPercentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 19

Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

Time frame:
Visit 19 (Month 51)
Reported as:
Number · percentage of participants
Percentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 19
percentage of participantsN159 PBO/LEVN159 LEV/LEVN01010+N151 LEV/LEVN01052 LEV/LEV
Marked improvement9.17.70.0—
Moderate improvement0.07.70.0—
Slight improvement18.215.440.0—
No change54.546.260.0—
Slight worsening18.223.10.0—
Moderate worsening0.00.00.0—
Marked worsening0.00.00.0—
Not done0.00.00.0—
SecondaryPercentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 20

Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

Time frame:
Visit 20 (Month 54)
Reported as:
Number · percentage of participants
Percentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 20
percentage of participantsN159 PBO/LEVN159 LEV/LEVN01010+N151 LEV/LEVN01052 LEV/LEV
Marked improvement0.08.30.0—
Moderate improvement9.10.00.0—
Slight improvement18.216.70.0—
No change63.658.3100.0—
Slight worsening9.18.30.0—
Moderate worsening0.08.30.0—
Marked worsening0.00.00.0—
Not done0.00.00.0—
SecondaryPercentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 21

Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

Time frame:
Visit 21 (Month 57)
Reported as:
Number · percentage of participants
Percentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 21
percentage of participantsN159 PBO/LEVN159 LEV/LEVN01010+N151 LEV/LEVN01052 LEV/LEV
Marked improvement22.20.00.0—
Moderate improvement0.012.50.0—
Slight improvement22.212.520.0—
No change55.662.580.0—
Slight worsening0.012.50.0—
Moderate worsening0.00.00.0—
Marked worsening0.00.00.0—
Not done0.00.00.0—
SecondaryPercentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 22

Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

Time frame:
Visit 22 (Month 60)
Reported as:
Number · percentage of participants
Percentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 22
percentage of participantsN159 PBO/LEVN159 LEV/LEVN01010+N151 LEV/LEVN01052 LEV/LEV
Marked improvement33.30.00.0—
Moderate improvement0.00.020.0—
Slight improvement0.00.020.0—
No change33.375.060.0—
Slight worsening33.30.00.0—
Moderate worsening0.025.00.0—
Marked worsening0.00.00.0—
Not done0.00.00.0—
SecondaryPercentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 23

Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

Time frame:
Visit 23 (Month 63)
Reported as:
Number · percentage of participants
Percentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 23
percentage of participantsN159 PBO/LEVN159 LEV/LEVN01010+N151 LEV/LEVN01052 LEV/LEV
Marked improvement0.00.00.0—
Moderate improvement0.00.020.0—
Slight improvement50.0100.020.0—
No change50.00.040.0—
Slight worsening0.00.00.0—
Moderate worsening0.00.020.0—
Marked worsening0.00.00.0—
Not done0.00.00.0—
SecondaryPercentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 24

Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

Time frame:
Visit 24 (Month 66)
Reported as:
Number · percentage of participants
Percentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 24
percentage of participantsN159 PBO/LEVN159 LEV/LEVN01010+N151 LEV/LEVN01052 LEV/LEV
Marked improvement0.0—20.0—
Moderate improvement0.0—0.0—
Slight improvement0.0—0.0—
No change100.0—80.0—
Slight worsening0.0—0.0—
Moderate worsening0.0—0.0—
Marked worsening0.0—0.0—
Not done0.0—0.0—
SecondaryPercentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 25

Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

Time frame:
Visit 25 (Month 69)
Reported as:
Number · percentage of participants
Percentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 25
percentage of participantsN159 PBO/LEVN159 LEV/LEVN01010+N151 LEV/LEVN01052 LEV/LEV
Marked improvement——0.0—
Moderate improvement——0.0—
Slight improvement——0.0—
No change——100.0—
Slight worsening——0.0—
Moderate worsening——0.0—
Marked worsening——0.0—
Not done——0.0—
SecondaryPercentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 26

Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

Time frame:
Visit 26 (Month 72)
Reported as:
Number · percentage of participants
Percentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 26
percentage of participantsN159 PBO/LEVN159 LEV/LEVN01010+N151 LEV/LEVN01052 LEV/LEV
Marked improvement——0.0—
Moderate improvement——25.0—
Slight improvement——0.0—
No change——75.0—
Slight worsening——0.0—
Moderate worsening——0.0—
Marked worsening——0.0—
Not done——0.0—
SecondaryPercentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 27

Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

Time frame:
Visit 27 (Month 75)
Reported as:
Number · percentage of participants
Percentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 27
percentage of participantsN159 PBO/LEVN159 LEV/LEVN01010+N151 LEV/LEVN01052 LEV/LEV
Marked improvement——0.0—
Moderate improvement——25.0—
Slight improvement——0.0—
No change——75.0—
Slight worsening——0.0—
Moderate worsening——0.0—
Marked worsening——0.0—
Not done——0.0—
SecondaryPercentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 28

Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

Time frame:
Visit 28 (Month 78)
Reported as:
Number · percentage of participants
Percentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 28
percentage of participantsN159 PBO/LEVN159 LEV/LEVN01010+N151 LEV/LEVN01052 LEV/LEV
Marked improvement——0.0—
Moderate improvement——0.0—
Slight improvement——0.0—
No change——100.0—
Slight worsening——0.0—
Moderate worsening——0.0—
Marked worsening——0.0—
Not done——0.0—
SecondaryPercentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 29

Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

Time frame:
Visit 29 (Month 81)
Reported as:
Number · percentage of participants
Percentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 29
percentage of participantsN159 PBO/LEVN159 LEV/LEVN01010+N151 LEV/LEVN01052 LEV/LEV
Marked improvement——0.0—
Moderate improvement——0.0—
Slight improvement——0.0—
No change——75.0—
Slight worsening——25.0—
Moderate worsening——0.0—
Marked worsening——0.0—
Not done——0.0—
SecondaryPercentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 30

Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

Time frame:
Visit 30 (Month 84)
Reported as:
Number · percentage of participants
Percentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 30
percentage of participantsN159 PBO/LEVN159 LEV/LEVN01010+N151 LEV/LEVN01052 LEV/LEV
Marked improvement——0.0—
Moderate improvement——0.0—
Slight improvement——0.0—
No change——100.0—
Slight worsening——0.0—
Moderate worsening——0.0—
Marked worsening——0.0—
Not done——0.0—
SecondaryPercentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 31

Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

Time frame:
Visit 31 (Month 87)
Reported as:
Number · percentage of participants
Percentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 31
percentage of participantsN159 PBO/LEVN159 LEV/LEVN01010+N151 LEV/LEVN01052 LEV/LEV
Marked improvement——0.0—
Moderate improvement——0.0—
Slight improvement——0.0—
No change——100.0—
Slight worsening——0.0—
Moderate worsening——0.0—
Marked worsening——0.0—
Not done——0.0—
SecondaryPercentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Withdrawal Visit

Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

Time frame:
Withdrawal visit (up to Month 90)
Reported as:
Number · percentage of participants
Percentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Withdrawal Visit
percentage of participantsN159 PBO/LEVN159 LEV/LEVN01010+N151 LEV/LEVN01052 LEV/LEV
Marked improvement5.90.00.00.0
Moderate improvement5.97.10.00.0
Slight improvement5.90.020.025.0
No change41.250.00.075.0
Slight worsening11.835.760.00.0
Moderate worsening23.50.020.00.0
Marked worsening5.97.10.00.0
Not done0.00.00.00.0
SecondaryPercentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Final Visit

Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

Time frame:
Final visit (up to Month 90)
Reported as:
Number · percentage of participants
Percentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Final Visit
percentage of participantsN159 PBO/LEVN159 LEV/LEVN01010+N151 LEV/LEVN01052 LEV/LEV
Marked improvement4.33.72.47.7
Moderate improvement11.66.217.10.0
Slight improvement23.29.914.67.7
No change36.261.751.269.2
Slight worsening17.49.94.915.4
Moderate worsening4.36.29.80.0
Marked worsening1.40.00.00.0
Not done1.42.50.00.0
SecondaryPercentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 1

Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit). The reference time point for Visit 1 is in the respective feeder study of the participant.

Time frame:
Visit 1 (Screening Visit (Week 0))
Reported as:
Number · percentage of participants
Percentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 1
percentage of participantsN159 PBO/LEVN159 LEV/LEVN01010+N151 LEV/LEVN01052 LEV/LEV
Marked improvement12.818.029.30.0
Moderate improvement16.715.714.60.0
Slight improvement17.919.114.60.0
No change41.038.224.492.9
Slight worsening7.77.917.17.1
Moderate worsening3.80.00.00.0
Marked worsening0.00.00.00.0
Not done0.01.10.00.0
SecondaryPercentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Titration Visit 1

Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

Time frame:
Titration Visit 1 (Week 2)
Reported as:
Number · percentage of participants
Percentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Titration Visit 1
percentage of participantsN159 PBO/LEVN159 LEV/LEVN01010+N151 LEV/LEVN01052 LEV/LEV
Marked improvement17.611.0——
Moderate improvement18.911.0——
Slight improvement32.417.1——
No change25.748.8——
Slight worsening4.18.5——
Moderate worsening0.01.2——
Marked worsening0.00.0——
Not done1.42.4——
SecondaryPercentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Titration Visit 2

Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

Time frame:
Titration Visit 2 (Week 4)
Reported as:
Number · percentage of participants
Percentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Titration Visit 2
percentage of participantsN159 PBO/LEVN159 LEV/LEVN01010+N151 LEV/LEVN01052 LEV/LEV
Marked improvement17.316.7——
Moderate improvement16.010.7——
Slight improvement20.015.5——
No change36.039.3——
Slight worsening6.715.5——
Moderate worsening2.71.2——
Marked worsening0.00.0——
Not done1.31.2——
SecondaryPercentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Titration Visit 3

Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

Time frame:
Titration Visit 3 (Week 6)
Reported as:
Number · percentage of participants
Percentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Titration Visit 3
percentage of participantsN159 PBO/LEVN159 LEV/LEVN01010+N151 LEV/LEVN01052 LEV/LEV
Marked improvement10.44.1——
Moderate improvement9.012.3——
Slight improvement20.927.4——
No change43.341.1——
Slight worsening9.08.2——
Moderate worsening3.04.1——
Marked worsening1.51.4——
Not done3.01.4——
SecondaryPercentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 2

Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

Time frame:
Visit 2 (Month 2)
Reported as:
Number · percentage of participants
Percentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 2
percentage of participantsN159 PBO/LEVN159 LEV/LEVN01010+N151 LEV/LEVN01052 LEV/LEV
Marked improvement6.813.125.616.7
Moderate improvement17.811.915.48.3
Slight improvement21.916.720.541.7
No change30.145.217.98.3
Slight worsening17.84.817.90.0
Moderate worsening2.74.82.68.3
Marked worsening2.71.20.016.7
Not done0.02.40.00.0
SecondaryPercentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 3

Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

Time frame:
Visit 3 (Month 4)
Reported as:
Number · percentage of participants
Percentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 3
percentage of participantsN159 PBO/LEVN159 LEV/LEVN01010+N151 LEV/LEVN01052 LEV/LEV
Marked improvement8.86.518.420.0
Moderate improvement5.96.515.820.0
Slight improvement16.213.018.420.0
No change38.248.136.830.0
Slight worsening19.122.17.910.0
Moderate worsening10.33.92.60.0
Marked worsening1.50.00.00.0
Not done0.00.00.00.0
SecondaryPercentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 4

Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

Time frame:
Visit 4 (Month 6)
Reported as:
Number · percentage of participants
Percentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 4
percentage of participantsN159 PBO/LEVN159 LEV/LEVN01010+N151 LEV/LEVN01052 LEV/LEV
Marked improvement4.88.020.020.0
Moderate improvement7.96.714.30.0
Slight improvement22.229.35.720.0
No change39.733.337.150.0
Slight worsening19.017.317.110.0
Moderate worsening4.85.35.70.0
Marked worsening1.60.00.00.0
Not done0.00.00.00.0
SecondaryPercentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 5

Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

Time frame:
Visit 5 (Month 9)
Reported as:
Number · percentage of participants
Percentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 5
percentage of participantsN159 PBO/LEVN159 LEV/LEVN01010+N151 LEV/LEVN01052 LEV/LEV
Marked improvement6.810.89.411.1
Moderate improvement10.26.29.433.3
Slight improvement25.412.39.411.1
No change33.946.250.033.3
Slight worsening20.315.49.40.0
Moderate worsening0.06.212.511.1
Marked worsening3.43.10.00.0
Not done0.00.00.00.0
SecondaryPercentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 6

Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

Time frame:
Visit 6 (Month 12)
Reported as:
Number · percentage of participants
Percentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 6
percentage of participantsN159 PBO/LEVN159 LEV/LEVN01010+N151 LEV/LEVN01052 LEV/LEV
Marked improvement7.48.214.311.1
Moderate improvement9.313.114.311.1
Slight improvement25.923.014.322.2
No change33.334.439.355.6
Slight worsening18.511.514.30.0
Moderate worsening3.78.23.60.0
Marked worsening1.91.60.00.0
Not done0.00.00.00.0
SecondaryPercentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 7

Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

Time frame:
Visit 7 (Month 15)
Reported as:
Number · percentage of participants
Percentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 7
percentage of participantsN159 PBO/LEVN159 LEV/LEVN01010+N151 LEV/LEVN01052 LEV/LEV
Marked improvement10.619.27.10.0
Moderate improvement10.69.67.10.0
Slight improvement23.47.710.737.5
No change29.840.442.937.5
Slight worsening19.115.425.012.5
Moderate worsening4.33.83.60.0
Marked worsening2.11.93.612.5
Not done0.01.90.00.0
SecondaryPercentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 8

Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

Time frame:
Visit 8 (Month 18)
Reported as:
Number · percentage of participants
Percentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 8
percentage of participantsN159 PBO/LEVN159 LEV/LEVN01010+N151 LEV/LEVN01052 LEV/LEV
Marked improvement5.015.77.116.7
Moderate improvement7.59.814.30.0
Slight improvement17.517.614.316.7
No change45.035.342.966.7
Slight worsening22.515.710.70.0
Moderate worsening2.53.910.70.0
Marked worsening0.02.00.00.0
Not done0.00.00.00.0
SecondaryPercentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 9

Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

Time frame:
Visit 9 (Month 21)
Reported as:
Number · percentage of participants
Percentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 9
percentage of participantsN159 PBO/LEVN159 LEV/LEVN01010+N151 LEV/LEVN01052 LEV/LEV
Marked improvement10.312.218.50.0
Moderate improvement7.710.27.40.0
Slight improvement10.314.322.240.0
No change56.453.133.340.0
Slight worsening10.36.13.70.0
Moderate worsening5.12.011.120.0
Marked worsening0.02.03.70.0
Not done0.00.00.00.0
SecondaryPercentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 10

Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

Time frame:
Visit 10 (Month 24)
Reported as:
Number · percentage of participants
Percentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 10
percentage of participantsN159 PBO/LEVN159 LEV/LEVN01010+N151 LEV/LEVN01052 LEV/LEV
Marked improvement8.68.512.00.0
Moderate improvement5.78.54.00.0
Slight improvement22.921.320.016.7
No change42.948.940.066.7
Slight worsening11.410.620.00.0
Moderate worsening5.72.10.016.7
Marked worsening2.90.04.00.0
Not done0.00.00.00.0
SecondaryPercentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 11

Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

Time frame:
Visit 11 (Month 27)
Reported as:
Number · percentage of participants
Percentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 11
percentage of participantsN159 PBO/LEVN159 LEV/LEVN01010+N151 LEV/LEVN01052 LEV/LEV
Marked improvement9.49.19.10.0
Moderate improvement9.44.522.720.0
Slight improvement18.818.29.120.0
No change53.145.554.540.0
Slight worsening6.311.44.520.0
Moderate worsening0.06.80.00.0
Marked worsening0.02.30.00.0
Not done3.12.30.00.0
SecondaryPercentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 12

Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

Time frame:
Visit 12 (Month 30)
Reported as:
Number · percentage of participants
Percentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 12
percentage of participantsN159 PBO/LEVN159 LEV/LEVN01010+N151 LEV/LEVN01052 LEV/LEV
Marked improvement6.77.70.00.0
Moderate improvement13.312.811.10.0
Slight improvement26.720.55.625.0
No change33.348.755.675.0
Slight worsening16.75.116.70.0
Moderate worsening3.32.611.10.0
Marked worsening0.00.00.00.0
Not done0.02.60.00.0
SecondaryPercentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 13

Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

Time frame:
Visit 13 (Month 33)
Reported as:
Number · percentage of participants
Percentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 13
percentage of participantsN159 PBO/LEVN159 LEV/LEVN01010+N151 LEV/LEVN01052 LEV/LEV
Marked improvement7.73.30.00.0
Moderate improvement23.16.711.10.0
Slight improvement15.423.322.225.0
No change38.546.755.675.0
Slight worsening15.416.711.10.0
Moderate worsening0.03.30.00.0
Marked worsening0.00.00.00.0
Not done0.00.00.00.0
SecondaryPercentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 14

Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

Time frame:
Visit 14 (Month 36)
Reported as:
Number · percentage of participants
Percentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 14
percentage of participantsN159 PBO/LEVN159 LEV/LEVN01010+N151 LEV/LEVN01052 LEV/LEV
Marked improvement20.04.20.0—
Moderate improvement0.04.20.0—
Slight improvement26.712.511.1—
No change40.050.066.7—
Slight worsening13.320.822.2—
Moderate worsening0.04.20.0—
Marked worsening0.04.20.0—
Not done0.00.00.0—
SecondaryPercentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 15

Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

Time frame:
Visit 15 (Month 39)
Reported as:
Number · percentage of participants
Percentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 15
percentage of participantsN159 PBO/LEVN159 LEV/LEVN01010+N151 LEV/LEVN01052 LEV/LEV
Marked improvement6.70.00.0—
Moderate improvement6.70.014.3—
Slight improvement40.028.614.3—
No change40.052.457.1—
Slight worsening6.79.514.3—
Moderate worsening0.04.80.0—
Marked worsening0.00.00.0—
Not done0.04.80.0—
SecondaryPercentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 16

Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

Time frame:
Visit 16 (Month 42)
Reported as:
Number · percentage of participants
Percentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 16
percentage of participantsN159 PBO/LEVN159 LEV/LEVN01010+N151 LEV/LEVN01052 LEV/LEV
Marked improvement7.10.00.0—
Moderate improvement21.40.00.0—
Slight improvement14.316.728.6—
No change35.755.671.4—
Slight worsening14.322.20.0—
Moderate worsening7.10.00.0—
Marked worsening0.05.60.0—
Not done0.00.00.0—
SecondaryPercentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 17

Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

Time frame:
Visit 17 (Month 45)
Reported as:
Number · percentage of participants
Percentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 17
percentage of participantsN159 PBO/LEVN159 LEV/LEVN01010+N151 LEV/LEVN01052 LEV/LEV
Marked improvement15.411.80.0—
Moderate improvement0.00.016.7—
Slight improvement38.523.50.0—
No change46.241.283.3—
Slight worsening0.017.60.0—
Moderate worsening0.05.90.0—
Marked worsening0.00.00.0—
Not done0.00.00.0—
SecondaryPercentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 18

Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

Time frame:
Visit 18 (Month 48)
Reported as:
Number · percentage of participants
Percentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 18
percentage of participantsN159 PBO/LEVN159 LEV/LEVN01010+N151 LEV/LEVN01052 LEV/LEV
Marked improvement0.015.416.7—
Moderate improvement0.07.70.0—
Slight improvement23.123.116.7—
No change38.538.550.0—
Slight worsening38.515.40.0—
Moderate worsening0.00.016.7—
Marked worsening0.00.00.0—
Not done0.00.00.0—
SecondaryPercentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 19

Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

Time frame:
Visit 19 (Month 51)
Reported as:
Number · percentage of participants
Percentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 19
percentage of participantsN159 PBO/LEVN159 LEV/LEVN01010+N151 LEV/LEVN01052 LEV/LEV
Marked improvement9.17.70.0—
Moderate improvement0.07.70.0—
Slight improvement27.323.140.0—
No change45.538.560.0—
Slight worsening18.223.10.0—
Moderate worsening0.00.00.0—
Marked worsening0.00.00.0—
Not done0.00.00.0—
SecondaryPercentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 20

Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

Time frame:
Visit 20 (Month 54)
Reported as:
Number · percentage of participants
Percentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 20
percentage of participantsN159 PBO/LEVN159 LEV/LEVN01010+N151 LEV/LEVN01052 LEV/LEV
Marked improvement9.18.30.0—
Moderate improvement9.10.00.0—
Slight improvement9.116.70.0—
No change63.666.7100.0—
Slight worsening9.10.00.0—
Moderate worsening0.08.30.0—
Marked worsening0.00.00.0—
Not done0.00.00.0—
SecondaryPercentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 21

Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

Time frame:
Visit 21 (Month 57)
Reported as:
Number · percentage of participants
Percentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 21
percentage of participantsN159 PBO/LEVN159 LEV/LEVN01010+N151 LEV/LEVN01052 LEV/LEV
Marked improvement22.20.00.0—
Moderate improvement0.00.020.0—
Slight improvement22.237.520.0—
No change55.650.060.0—
Slight worsening0.012.50.0—
Moderate worsening0.00.00.0—
Marked worsening0.00.00.0—
Not done0.00.00.0—
SecondaryPercentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 22

Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

Time frame:
Visit 22 (Month 60)
Reported as:
Number · percentage of participants
Percentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 22
percentage of participantsN159 PBO/LEVN159 LEV/LEVN01010+N151 LEV/LEVN01052 LEV/LEV
Marked improvement33.30.020.0—
Moderate improvement0.00.00.0—
Slight improvement0.00.020.0—
No change33.375.060.0—
Slight worsening33.30.00.0—
Moderate worsening0.025.00.0—
Marked worsening0.00.00.0—
Not done0.00.00.0—
SecondaryPercentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 23

Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

Time frame:
Visit 23 (Month 63)
Reported as:
Number · percentage of participants
Percentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 23
percentage of participantsN159 PBO/LEVN159 LEV/LEVN01010+N151 LEV/LEVN01052 LEV/LEV
Marked improvement0.00.00.0—
Moderate improvement50.00.020.0—
Slight improvement0.0100.020.0—
No change50.00.040.0—
Slight worsening0.00.00.0—
Moderate worsening0.00.020.0—
Marked worsening0.00.00.0—
Not done0.00.00.0—
SecondaryPercentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 24

Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

Time frame:
Visit 24 (Month 66)
Reported as:
Number · percentage of participants
Percentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 24
percentage of participantsN159 PBO/LEVN159 LEV/LEVN01010+N151 LEV/LEVN01052 LEV/LEV
Marked improvement0.0—20.0—
Moderate improvement0.0—0.0—
Slight improvement0.0—0.0—
No change100.0—80.0—
Slight worsening0.0—0.0—
Moderate worsening0.0—0.0—
Marked worsening0.0—0.0—
Not done0.0—0.0—
SecondaryPercentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 25

Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

Time frame:
Visit 25 (Month 69)
Reported as:
Number · percentage of participants
Percentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 25
percentage of participantsN159 PBO/LEVN159 LEV/LEVN01010+N151 LEV/LEVN01052 LEV/LEV
Marked improvement——0.0—
Moderate improvement——0.0—
Slight improvement——0.0—
No change——100.0—
Slight worsening——0.0—
Moderate worsening——0.0—
Marked worsening——0.0—
Not done——0.0—
SecondaryPercentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 26

Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

Time frame:
Visit 26 (Month 72)
Reported as:
Number · percentage of participants
Percentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 26
percentage of participantsN159 PBO/LEVN159 LEV/LEVN01010+N151 LEV/LEVN01052 LEV/LEV
Marked improvement——0.0—
Moderate improvement——25.0—
Slight improvement——0.0—
No change——75.0—
Slight worsening——0.0—
Moderate worsening——0.0—
Marked worsening——0.0—
Not done——0.0—
SecondaryPercentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 27

Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

Time frame:
Visit 27 (Month 75)
Reported as:
Number · percentage of participants
Percentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 27
percentage of participantsN159 PBO/LEVN159 LEV/LEVN01010+N151 LEV/LEVN01052 LEV/LEV
Marked improvement——0.0—
Moderate improvement——25.0—
Slight improvement——0.0—
No change——75.0—
Slight worsening——0.0—
Moderate worsening——0.0—
Marked worsening——0.0—
Not done——0.0—
SecondaryPercentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 28

Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

Time frame:
Visit 28 (Month 78)
Reported as:
Number · percentage of participants
Percentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 28
percentage of participantsN159 PBO/LEVN159 LEV/LEVN01010+N151 LEV/LEVN01052 LEV/LEV
Marked improvement——0.0—
Moderate improvement——0.0—
Slight improvement——0.0—
No change——100.0—
Slight worsening——0.0—
Moderate worsening——0.0—
Marked worsening——0.0—
Not done——0.0—
SecondaryPercentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 29

Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

Time frame:
Visit 29 (Month 81)
Reported as:
Number · percentage of participants
Percentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 29
percentage of participantsN159 PBO/LEVN159 LEV/LEVN01010+N151 LEV/LEVN01052 LEV/LEV
Marked improvement——0.0—
Moderate improvement——0.0—
Slight improvement——0.0—
No change——75.0—
Slight worsening——25.0—
Moderate worsening——0.0—
Marked worsening——0.0—
Not done——0.0—
SecondaryPercentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 30

Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

Time frame:
Visit 30 (Month 84)
Reported as:
Number · percentage of participants
Percentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 30
percentage of participantsN159 PBO/LEVN159 LEV/LEVN01010+N151 LEV/LEVN01052 LEV/LEV
Marked improvement——0.0—
Moderate improvement——0.0—
Slight improvement——0.0—
No change——100.0—
Slight worsening——0.0—
Moderate worsening——0.0—
Marked worsening——0.0—
Not done——0.0—
SecondaryPercentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 31

Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

Time frame:
Visit 31 (Month 87)
Reported as:
Number · percentage of participants
Percentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 31
percentage of participantsN159 PBO/LEVN159 LEV/LEVN01010+N151 LEV/LEVN01052 LEV/LEV
Marked improvement——0.0—
Moderate improvement——0.0—
Slight improvement——0.0—
No change——100.0—
Slight worsening——0.0—
Moderate worsening——0.0—
Marked worsening——0.0—
Not done——0.0—
SecondaryPercentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Withdrawal Visit

Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

Time frame:
Withdrawal visit (up to Month 90)
Reported as:
Number · percentage of participants
Percentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Withdrawal Visit
percentage of participantsN159 PBO/LEVN159 LEV/LEVN01010+N151 LEV/LEVN01052 LEV/LEV
Marked improvement5.97.10.00.0
Moderate improvement0.00.00.00.0
Slight improvement5.90.020.025.0
No change41.242.940.075.0
Slight worsening29.421.420.00.0
Moderate worsening17.614.320.00.0
Marked worsening0.07.10.00.0
Not done0.07.10.00.0
SecondaryPercentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Final Visit

Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).

Time frame:
Final visit (up to Month 90)
Reported as:
Number · percentage of participants
Percentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Final Visit
percentage of participantsN159 PBO/LEVN159 LEV/LEVN01010+N151 LEV/LEVN01052 LEV/LEV
Marked improvement8.77.44.97.7
Moderate improvement14.58.612.20.0
Slight improvement15.96.214.67.7
No change34.858.051.269.2
Slight worsening17.413.64.915.4
Moderate worsening0.03.74.90.0
Marked worsening5.81.27.30.0
Not done2.91.20.00.0

Adverse events

Collected over Adverse events were collected from first dose in N157 to End of the Study (up to 7.5 years). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
N159 PBO/LEV0/79 (0%)20/79 (25.3%)77/79 (97.5%)
N159 LEV/LEV1/89 (1.1%)35/89 (39.3%)86/89 (96.6%)
N01010+N151 LEV/LEV0/41 (0%)12/41 (29.3%)41/41 (100%)
N01052 LEV/LEV0/14 (0%)7/14 (50%)13/14 (92.9%)
Most frequent serious events
Showing 10 of 54
Most frequent serious events
EventN159 PBO/LEVN159 LEV/LEVN01010+N151 LEV/LEVN01052 LEV/LEV
ConvulsionNervous system disorders9/797/892/414/14
Procedure therapeutic epilepsyInvestigations2/798/895/410/14
Procedure diagnostic epilepsyInvestigations2/799/891/410/14
CystGeneral disorders0/790/890/411/14
HypothermiaGeneral disorders0/790/890/411/14
InfectionGeneral disorders0/790/890/411/14
ConstipationGastrointestinal disorders0/790/890/411/14
Gastrointestinal disorderGastrointestinal disorders0/790/890/411/14
DehydrationMetabolism and nutrition disorders1/790/890/411/14
Status epilepticusNervous system disorders1/791/890/411/14
Most frequent other events
Showing 10 of 89
Most frequent other events
EventN159 PBO/LEVN159 LEV/LEVN01010+N151 LEV/LEVN01052 LEV/LEV
InfectionGeneral disorders46/7948/8920/4110/14
FeverGeneral disorders24/7923/899/417/14
Otitis mediaEar and labyrinth disorders17/7919/899/417/14
HeadacheGeneral disorders19/7923/8915/410/14
NervousnessNervous system disorders1/795/8914/412/14
Accidental injuryGeneral disorders18/7926/899/413/14
AnorexiaGastrointestinal disorders7/798/896/414/14
GastroenteritisGastrointestinal disorders14/798/894/414/14
VomitingGastrointestinal disorders15/7916/8911/414/14
Respiratory disorderRespiratory, thoracic and mediastinal disorders1/791/892/414/14

Baseline characteristics

Baseline characteristics refer to the Intention-to-treat (ITT) Set which consisted of all subjects who took at least one dose of levetiracetam in study N157 excluding subjects from one site due to the unreliability of the data reported.

Age, Categorical
Age, Categorical(Participants)N159 PBO/LEVN159 LEV/LEVN01010+N151 LEV/LEVN01052 LEV/LEVTotal Title
<=18 years79894114223
Between 18 and 65 years00000
>=65 years00000
Age, Continuous
Age, Continuous(years)N159 PBO/LEVN159 LEV/LEVN01010+N151 LEV/LEVN01052 LEV/LEVTotal Title
Mean9.88 ± 3.4610.61 ± 3.2410.07 ± 2.201.62 ± 1.169.68 ± 3.72
Sex: Female, Male
Sex: Female, Male(Participants)N159 PBO/LEVN159 LEV/LEVN01010+N151 LEV/LEVN01052 LEV/LEVTotal Title
Female4339167105
Male3650257118
08

Study locations

No study locations are listed for this record.

09

References and documents

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 1998 to primary completion in Jan 2006, 95 months.

Results were first posted in Feb 2024, 18 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 6, 2005
First posted
Sep 8, 2005
StartActual
Jan 26, 1998
Primary completionActual
Jan 25, 2006
CompletionActual
Jan 25, 2006
Results first posted
Feb 9, 2024
Last update
Feb 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00150709
Lead sponsor
UCB Pharma
Responsible party
Sponsor
First posted
Sep 8, 2005
Start date
Jan 26, 1998
Primary completion
Jan 25, 2006
Completion
Jan 25, 2006
Results posted
Feb 9, 2024
Last update
Feb 9, 2024

Study contacts

UCB Cares
study director · 001 844 599 2273 (UCB)

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Levetiracetam

Start the discussion